Resistant hypertension (RH) is a multifactorial chronic condition in which the blood pressure (BP) remains above the recommended goals 1 of ≥140/90 mm Hg for the general population or ≥130/80 mm Hg for patients with chronic kidney disease or diabetes, despite the use at least 3 antihypertensive medications in adequate doses. 2 Cardiovascular (CV) events and renal failure are related to both the degree and duration of BP increase. Thus, RH subjects have higher CV events and target organ damage (TOD), such as left ventricular hypertrophy, arterial stiffness, and microalbuminuria, compared with those whose antihypertensive treatment is able to achieve BP control. Additionally, type 2 diabetes mellitus (T2DM) is also associated with CV and renal events, and when combined with RH, the complications related with the development of TODs are even higher. The major goal toward lowering the global burden of CV complications in hypertension is decreasing BP levels and TODs. 3 Sodium glucose cotransporter 2 (SGLT-2) inhibitors-the most recent opportunity for the management of T2DM, have been associated with BP lowering which could be pointed as a potential "add-on" pharmacologic strategy for hypertensive subjects. SGLT-2 inhibitors are a class of oral antidiabetic drugs that reduce hyperglycemia through inhibition of sodium and glucose reabsorption in the proximal tubule by blocking SGLT-2. Data from several experimental and clinical studies have demonstrated that SGLT-2 inhibitors not only improve glucose control, 4 weight loss, 5 and BP levels, 6 but they also reduce CV event. 7-9 Therefore, it could be argued that SGLT-2 inhibitors could play a role in the management of RH subjects not only for their antidiabetic effect but also for their "pleiotropic" CV effects. In this review, we summarize the major findings related to SGLT-2 inhibitors effects on TODs (Figure 1 ) and CV alterations (Table 1) and we also discuss the potential benefits of SGLT-2 inhibitors in hypertensive and more specifically in RH subjects.
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MICROALBUMINURIA
Microalbuminuria is defined as an increase in albumin levels released in urine (30-300 µg/mg). 10 It is considered an initial marker of renal injury and tends to increase according to the severity of hypertension. 11 The relationship between albumin excretion levels and CV risk can be used to predict CV morbidity and mortality in hypertensive patients. 12 Albuminuria is also associated with higher levels of BP and unfavorable lipid profile. 13 Individuals with RH have large adverse CV events mainly when renal function begins to decline and more antihypertensive drugs are needed to maintain BP targets. 14, 15 Oliveiras et al. 16 showed that microalbuminuria can predict high systolic BP, characterizing a reliable marker of true RH. Resistant hypertension (RH) is a multifactorial disease associated with several target organ damage, such as microalbuminuria, left ventricular hypertrophy, and arterial stiffness. These subjects have high cardiovascular complications, especially when associated with diabetes condition. Sodium glucose cotransporter 2 (SGLT-2) inhibitors represent a new class of oral antidiabetic drugs that have shown positive effects in diabetics and even hypertensives subjects. Several studies demonstrated positive outcomes related to blood pressure levels, body weight, and glycemic control. Also found a reduction on microalbuminuria, cardiac and arterial remodeling process, and decrease in hospitalization care due heart failure. Despite these positive effects, the outcomes found for stroke were conflicted and tend neutral effect. Based on this, we sought to assess the pleiotropic effects of SGLT-2 inhibitors and the possible impact in RH subjects. In order to analyze the prospects of SGLT-2 inhibitors as a possible medication to complement the therapy manage of this high-risk class of patients.
Keywords: arterial stiffness; blood pressure; heart failure; hypertension; left ventricular hypertrophy; microalbuminuria; resistant hypertension; SGLT-2 inhibitors; stroke; target organ damage. Positive results in renal damage were found with the administration of SGLT-2 inhibitors in animals and humans. The supplementary use of tofogliflozin during 5 weeks reduced albuminuria and tubulointerstitial lesion in obese T2DM animals. 17 Similar data were found with ipagliflozin in type 1 diabetic mice. 18 Gembardt et al. 19 found no impact on glomerular hypertrophy with empagliflozin but ameliorated albuminuria by 70%. In general, experimental data using inhibition of SGLT-2 suggest that the inhibition of glucose overload into tubular cells may exert a renoprotective effect due to the reduction on oxidative-stress generation, monocyte chemoattractant protein-1 expression, and apoptotic cell death in proximal tubular cells. 17 Clinical trials also found favorable renal outcomes; however, the results alter according to the tested drug and associated comorbidities. The use of dapagliflozin decreased albuminuria levels in hypertensive and T2DM subjects 20 and it showed a reduce urine albumin-to-creatinine ratio in subjects with T2DM and basal albuminuria. 21 Similarly, canagliflozin reduces microalbuminuria in subjects with installed renal damage 22 and empagliflozin besides reducing albuminuria levels also decrease the risk of developing macroalbuminuria. 23, 24 The renoprotective effects of SGLT-2 inhibitors probably are independent of glycemic control. They may be related to increased tubuloglomerular feedback, causing reduction in intraglomerular pressure and in the estimated glomerular filtration rate. 20, 22 In the CANVAS-R outcome recently published, subjects receiving canagliflozin demonstrated less progression of albuminuria, compared to placebo. This result uphold to the possible renal protection with the use of SGLT-2 inhibitors. 9 The current perspective is that initial renal damage might be reversed by lowering capillary pressure through drug therapy addition. Although most of the SGLT-2 inhibitors studies were not conducted specifically in hypertensive subjects, we may suggest that hypertensive and RH subjects could also have a renal benefit with these drugs, since the prognosis of renal injury is similar in diabetics and hypertensive patients.
HEART FAILURE
Several factors are related to the development of heart failure (HF), such as lifestyle, age, diabetes, and obesity, but hypertension is the condition most often associated with it. HF results in higher morbidity and mortality in hypertensive subjects. 25 RH are generally carriers of coronary heart disease, 26 so they have an increased risk of developing and progressing HF independently of BP levels and symptoms of coronary heart disease. 26, 27 Among antihypertensive drugs, diuretics are widely used to ameliorate the signs and symptoms of HF, but their administration may bring some inconvenience to patients such as the stimulation of the renin-angiotensin system induced by loop diuretics. 28, 29 SGLT-2 inhibitors may be an advantageous option for they have an osmotic diuretic effect because of their natriuretic mechanism 30 and may present better response than conventional diuretics since significant reduction in heart rate 31 with low adverse effects 32 were demonstrated by some studies. 33 Another point worthy of attention is the use of SGLT-2 Inhibitors and aldosterone antagonists. Canagliflozin was associated with increased serum potassium levels 34 and patients treated with aldosterone antagonists are at increased risk of hyperkalemia, therefore, it would be counter-indicated to add a medication that could further aggravate this effect, especially in high-risk patients with RH and patients with HF. However, a pooled analysis with DM2 patients showed that the use of dapagliflozin did not increase serum potassium levels even in those who used angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or potassium-sparing diuretics. 33 In addition, studies such as CANVAS 9 and EMPA-REG OUTCOME, 35 detailed ahead, also observed that SGLT-2 inhibitors decreased the cases of hospitalization for HF compared to placebo in DM2 patients. Therefore, even with these results indicating safety in the use of this new class of antidiabetics, its use should be evaluated according to the profile of each patient.
A multitude of trials primarily designed to assess CV safety were conducted with SGLT-2 inhibitors. However, none of them specifically assessed the effects of SGLT-2 inhibitors in HF patients. Subgroup analyses of EMPA-REG OUTCOME trial were performed in groups defined by baseline characteristics, including the presence/absence of investigatorreported HF. The findings were a reduction of approximately 34% in hospitalization risk or death from HF causes with the use of empagliflozin. Interestingly, despite the higher incidence rate hospitalization in subjects with HF compared with those without HF, this reduction with empagliflozin was consistent in both groups. 35 Additionally, a recent metaanalysis found beneficial estimate in hospitalization for HF causes with dapagliflozin in a broad population of subjects with varying risk for CV events. 36 Considering that SGLT-2 inhibitors have beneficial mechanisms on HF involving osmotic diuresis modulation on cardio-renal axis, reduction in arterial stiffness and BP levels, 35 we might speculate that the association of SGLT-2 inhibitors with traditional antihypertensive drugs could result in a better prognosis for RH subjects with HF.
Further mechanistic studies and clinical trials are needed to provide additional information regarding the effects and mechanisms of SGLT-2 inhibitors in HF. Currently, at least 2 studies are ongoing: (i) the CANDLE study-designed to evaluate the safety and noninferiority of canagliflozin compared to glimepiride in diabetic patients with chronic HF 37 and (ii) REFORM trial-designed to test the potential CV benefits of dapagliflozin in the diabetic HF population. 32 If these studies show a beneficial effect on cardiac remodeling and others HF parameters, the SGLT-2 inhibitors would probably be above other therapeutic drugs for use in HF patients with diabetes and possibly along with hypertensive or RH subjects.
STROKE
RH is associated with an increased risk of major adverse CV and cerebrovascular events, primarily nonfatal stroke. 38 We could initially assume-based on the CV effects and their BP-lowering effects-that the use of SGLT-2 inhibitors may bring additional benefits in hypertensive patients for stroke prevention, 39 Both CANVAS and the EMPA-REG OUTCOME trials showed neutral effect in the incidence of stroke using canagliflozin and empagliflozin, respectively, compared with placebo. 9 There was even a tendency for higher stroke risk using empagliflozin. [40] [41] [42] In order to explain these results, 2 hypotheses related to the effect of SGLT-2 inhibitors and the increased risk of stroke emerged: (i) the combination of SGLT-2 inhibitors with diuretics could cause massive diuresis leading to dehydration and hypotension facilitating cerebral infarction 7, 43 ; and (ii) excessive osmotic diuresis may also cause an increase in hematocrit Abbreviations: HT, hypertensive subjects; LVH, left ventricular hypertrophy; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UACR, urine albumin-to-creatinine ratio. levels 44 resulting in high blood viscosity, that is closely linked to the risk of CV disease and mortality. 45 Considering the definition and therapeutic strategy used by RH subjects, in which diuretics are necessarily used, it is reasonable to presume that the risk of stroke in these patients could not be diminished when SGLT-2 inhibitors are added to the regimen treatment. Therefore, a close monitoring could be necessary in this situation, especially in the elderly (who are more predisposed to dehydration).
Despite these potential stroke risks under the SGLT-2 inhibitors use, this class of medication has been shown to have several beneficial outcomes as described above. Thus, additional studies are needed to assess this issue since the precise mechanism involving SGLT-2 inhibitors and stroke has not been elucidated.
LEFT VENTRICULAR HYPERTROPHY
Left ventricular hypertrophy is characterized by structural and functional alterations that occur due to an increase in the cardiac output enhancing the size and thickness of the left ventricle (LV). 46 LV remodeling is very common in untreated or difficult-to-control hypertensive subjects and may contribute to congestive HF, which is a major factor in increased CV risk and death. [47] [48] [49] Thus, the use of a medication that decreases or delay the process of cardiac remodeling would be important to improve the condition of individuals with left ventricular hypertrophy.
In order to analyze this parameter with SGLT-2 inhibitors, Verma et al. 50 performed an echocardiographic analysis in 10 subjects with T2DM and CV diseases after a 3-month treatment with 10 mg/day empagliflozin. They found a significant reduction in the LV mass index (88 ± 21 vs. 75 ± 19 g/ m 2 , P = 0.01) and improved diastolic function [8.5 ± 1.6 vs. 9.6 ± 1.3 cm/s, P = 0.002(e′)] in the treatment group compared to placebo group. The authors speculated some possible mechanisms for that: (i) the reduction of intravascular volume and increase of sodium excretion caused by the medication may favor the conditions of cardiac load and (ii) the increase in adenosine triphosphate, a more potent substrate for the myocardium, which has higher levels with the use of SGLT-2 inhibitors, may have effects on ventricular structure and function.
In addition, experimental data suggest that the beneficial cardiac effect of this class is linked to the indirect action in cardiac oxidative stress, cardiac fibrosis, cardiac hypertrophy, and inflammatory process, 51 which may result in an improvement on the progression of the hypertrophic phenotype. 52 This amelioration in cardiac remodeling occurred even without a significant reduction in BP, triglyceride, or lipid levels. 51 Unfortunately, the clinical and experimental results currently found are insufficient to predict the exact mechanism of SGLT-2 inhibitors in cardiac remodeling, but the available data suggesting these effects could be also extrapolated to RH patients-since this subset of hypertensive has more TODs, thus more cardiac remodeling especially with diastolic dysfunction. In addition, the BP-lowering effects of SGLT-2 inhibitors 6 may provide an additional clinical advantage for most individuals with difficult-to-control hypertension. 53 There are still few studies related to SGLT-2 inhibitors and left ventricular hypertrophy, but the ongoing REFORM study has as primary outcome to detect changes in the final systolic and left ventricular end-diastolic volumes and as a secondary outcome to analyze the LV ejection fraction and the index of LV mass. Thus, these outcomes may bring us more solid results on this issue. 32 
ARTERIAL STIFFNESS
The vascular system is particularly important in BP control since its dysfunction is involved in both cause and consequence of hypertension. Chronic BP overloading reduces elasticity and increases arterial stiffness, vascular tonus, and arterial endothelial dysfunction. 54, 55 Vascular damage is associated with HF and higher risk of mortality in hypertensive patients, mainly in RH. [56] [57] [58] Other factors, such as age, low nitric oxide levels, obesity, hypercholesterolemia, diabetes, and smoking related to arterial stiffness and systemic endothelial dysfunction are important to be highlighted. 59 Assessment of vascular properties is important to identify arterial stiffness and for stratifying CV risk. Aortic pulse wave velocity-a known method for detecting arterial stiffness-represents the integrated and cumulative effects of long-term exposure to all CV risk factors. The common lack of BP control presented by RH is likely to be a key contributing factor accelerating arterial rigidity. 60 There are few studies assessing the SGLT-2 inhibitors action in vascular remodeling and none of them were specifically designed to investigate the pulse wave velocity parameter-the gold standard for arterial stiffness measurement. 61 Post-hoc analyses were conducted from a phase III trial in patients with T2DM and hypertension receiving empagliflozin. Although Chilton et al. 62 found favorable effects on arterial stiffness and vascular resistance, they used only pulse pressure, mean arterial pressure, and diastolic pressure as markers of arterial stiffness. The authors also observed no increase in pulse rate, suggesting a relative reduction in the sympathetic nervous system tonus induced by SGLT-2 inhibitors use.
Cherney et al. 63 investigated the mechanistic basis for the BP-lowering effect of empagliflozin focusing on vascular damage and neurohormonal activation due to the known correlation of these parameters with BP. They found no influence of empagliflozin on heart rate but found significant reduces in pulse wave velocity. Since the beneficial hemodynamic changes observed in this trial were unlike to be accounted for nitric oxide levels, rennin-angiotensin-aldosterone system or sympathetic nervous system activity changes, the authors proposed that the improvement found on arterial compliance could be related to a combination of several others factors: (i) weight loss-reduction in weight independently decreased BP and arterial stiffness 64 ; (ii) glycemic control-low insulin doses have been correlated with improved arterial compliance 65 ; and (iii) diuretic effectdirect effects on vascular smooth muscle relaxation after induction of a negative sodium balance. 66 Indeed, obesity and insulin resistance have been pointed as metabolic conditions with great importance for causing resistance to antihypertensive treatment. Thus, it is reasonable to infer that drugs that decrease BP levels, adipose tissue and glycemic levels may improve the clinical condition of RH subjects. On the other hand, the modest weight loss and BP reduction attributed to SGLT-2 inhibitors could not be the only responsible for the decrease on CV risk. Possibly, the pleiotropic effects of SGLT-2 inhibitors may modulate some molecular and biochemical pathways related to CV outcomes, such as reduction on oxidative stress and markers of inflammation and fibrosis (nuclear factor κβ and collagen IV expression). 67 Despite these data, there is a need for further studies confirming all these mechanisms.
CONCLUSION
Considering that high BP is the strongest modifiable risk factor for global death and disability from CV disease and the fact that RH have complex pathophysiology that increases the CV risk and renal damage causing TODs, the use of drugs that can both control BP levels and modify other risk factors could be considered as a promising therapeutic options for RH subjects.
Although influence of SGLT-2 inhibitors specifically on RH subjects has not been studied, we can speculate that the benefits of this new class of oral antidiabetic drugs could also be extrapolated to these individuals. Obviously specific studies in this extreme phenotype subgroup would be needed, but based on what has been found so far, we believe in encouraging results.
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